InvestorsHub Logo
Followers 144
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

Re: None

Monday, 07/07/2014 7:15:54 AM

Monday, July 07, 2014 7:15:54 AM

Post# of 426504
I could not find the background of FDA' statement regarding HPS2-Thrive: "At the National Lipid Association 2013 conference, the HPS2-THRIVE results were presented along with a subgroup analysis of patients with elevated TG and low HDL-C at baseline; this subgroup did not appear distinct from the overall result (interaction p=0.95)"

As I know HPS2-Thrive subgroup analysis will be released during July (not confirmed, just expected). So what is the basis for this statement?

Slide Set of the results that were presented at the American College of Cardiology meeting on 9 March 2013
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News